Expression of these mutations in mouse models initiate hematologic malignancy characterized by an increase in early hematopoietic progenitors, splenomegaly, anemia, hypermethylated histones, and altered DNA methylation patterns similar to those found in patients with AML with IDH1/2 mutations. This evidence concerns the gene IDH1 and acute myeloid leukemia.